You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a pediatric population
|
|---|---|
| Published in |
BMC Infectious Diseases, August 2012
|
| DOI | 10.1186/1471-2334-12-179 |
| Pubmed ID | |
| Authors |
Stefano Rusconi, Vania Giacomet, Chiara Mameli, Alessandra Viganò, Ottavia Viganò, Fulvio Adorni, Massimo Galli, Gian Vincenzo Zuccotti |
| Abstract |
Although dual-boosted protease inhibitors regimen is not recommended in children with HIV infection, such a strategy could be useful in subjects with a complex resistance profile. This study was aimed at assessing the long term efficacy and safety of a double-boosted protease inhibitor combination, fosamprenavir (fAVP) and atazanavir/ritonavir (ATV/r) in a cohort of HIV-infected children and adolescents who had failed with nucleoside reverse transcriptase inhibitors. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 3% |
| Unknown | 30 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 8 | 26% |
| Researcher | 6 | 19% |
| Other | 4 | 13% |
| Student > Ph. D. Student | 3 | 10% |
| Professor > Associate Professor | 2 | 6% |
| Other | 6 | 19% |
| Unknown | 2 | 6% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 45% |
| Nursing and Health Professions | 5 | 16% |
| Immunology and Microbiology | 2 | 6% |
| Biochemistry, Genetics and Molecular Biology | 1 | 3% |
| Business, Management and Accounting | 1 | 3% |
| Other | 4 | 13% |
| Unknown | 4 | 13% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 January 2013.
All research outputs
#18,312,024
of 22,673,450 outputs
Outputs from BMC Infectious Diseases
#5,557
of 7,641 outputs
Outputs of similar age
#127,601
of 166,280 outputs
Outputs of similar age from BMC Infectious Diseases
#55
of 80 outputs
Altmetric has tracked 22,673,450 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 7,641 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one is in the 15th percentile – i.e., 15% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 166,280 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 10th percentile – i.e., 10% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 80 others from the same source and published within six weeks on either side of this one. This one is in the 20th percentile – i.e., 20% of its contemporaries scored the same or lower than it.